CA-INSEEGO
31.3.2021 15:07:07 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and IoT device-to-cloud solutions, today announced that its Wavemaker PRO 5G indoor router FX2000e has been certified for use in several markets globally. This plug-and-play fixed wireless solution provides 5G/LTE broadband with ethernet and Wi-Fi 6 connectivity for up to 32 devices, making it ideal for small businesses and distributed employees who need fast, reliable and highly secure internet access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005341/en/
With gigabit-class 5G speeds, the FX2000e delivers fast, reliable connectivity almost anywhere, from restaurant and retail locations to branch offices and home offices. The Inseego Mobile app provides an intuitive UI and makes it easy for end users to self-install their devices. Using Inseego Connect cloud softwarei , IT managers can remotely configure and manage all devices in a highly scalable deployment.
“5G solutions provide a great choice for broadband access for businesses and consumers in their distributed offices and homes,” said Inseego President of IoT & Mobile Solutions Ashish Sharma. “Our FX2000e is a compact solution that supports many different use cases for broadband connectivity: Small businesses can get fast internet access anywhere. Enterprises can easily deploy a secure WAN solution for their branch offices and remote employees. And SD WAN providers can now rely on a 5G WAN connection as a primary broadband connection for distributed locations.”
Flexible 5G connectivity
The FX2000e is certified to operate in a broad range of global 5G and 4G frequency bands. Designed as a powerful and cost-effective solution for last-mile internet access, it can bring high-speed broadband connectivity to users on leading 4G and 5G networks in global markets.
With its small form factor, the FX2000e can be deployed as the primary broadband solution for distributed retail locations, as an add-on WAN interface for SD WAN deployments, as an internet solution for small occupancy homes, or as a cable modem replacement for larger homes with mesh Wi-Fi systems and other connectivity needs.
Fast, flexible, reliable and secure
- Gigabit-class 5G and LTE speeds
- Robust connectivity with ethernet and Wi-Fi 6 for up to 32 devices
- Dual-SIM functionality for up to two carrier SIMs, with auto-switching between cellular networks and ethernet WAN
- Enterprise-grade security with OpenVPN, access control, end-to-end device security, threat identification, monitoring, threat alerts and other protectionsii
- Inseego Connect™ Advanced cloud management
- Continuous software updates, security and support
Availability
The Inseego Wavemaker™ PRO 5G indoor CPE FX2000e has received regulatory certifications for use in several regions worldwide, including FCC Band 48 support for CBRS networks, and is now available through major distributors in North America and Europe. Please contact Inseego to learn more.
A broad portfolio of 5G FWA solutions for consumers and enterprise customers
In addition to the FX2000e, the Inseego Wavemaker PRO portfolio includes the 5G indoor CPE FG2000e, which is currently commercially available in several markets. The portfolio also includes two 5G outdoor CPEs and a 5G industrial gateway. Please contact Inseego to learn more about these solutions.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide. To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp.
________________
i
Base version (free) enables a user to manage a single FX2000e device settings easily using the Inseego Mobile app or Web UI. For management of multiple devices, an Inseego Connect Standard or Inseego Connect Advanced subscription is required, providing advanced device management, provisioning, monitoring, and diagnostics for multiple devices from a single dashboard.
ii Contact Inseego to learn more about available advanced security solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005341/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom